Molecure S.A.

WSE:MOC 주식 보고서

시가총액: zł165.8m

Molecure 과거 수익 실적

과거 기준 확인 0/6

Molecure's earnings have been declining at an average annual rate of -44.8%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 31.2% per year.

주요 정보

-44.8%

수익 성장률

-42.6%

EPS 성장률

Pharmaceuticals 산업 성장29.4%
매출 성장률-31.2%
자기자본 수익률-38.4%
순이익-2,020.9%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

Recent updates

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Aug 20
Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Apr 20
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Dec 01
We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Jul 07
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Mar 10
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Aug 16
Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Nov 04
OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Feb 24
Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Jan 02
Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

수익 및 비용 분석

Molecure 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

WSE:MOC 수익, 비용 및 수입 (PLN Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 242-31260
30 Jun 242-30270
31 Mar 242-29270
31 Dec 234-28280
30 Sep 239-45450
30 Jun 238-42410
31 Mar 238-39380
31 Dec 228-36350
30 Sep 222-16160
30 Jun 222-16150
31 Mar 222-15140
31 Dec 211-14120
30 Sep 2112463140
30 Jun 2112464140
31 Mar 2112567120
31 Dec 2012568120
30 Sep 202-350
30 Jun 202-350
31 Mar 202-450
31 Dec 192-460
30 Sep 192-560
30 Jun 192-560
31 Mar 191-560
31 Dec 181-450
30 Sep 181-450
30 Jun 182-440
31 Mar 182-240
31 Dec 171-230
30 Sep 171-320
30 Jun 171-320
31 Mar 171-320
31 Dec 161-220
31 Dec 151-110

양질의 수익: MOC is currently unprofitable.

이익 마진 증가: MOC is currently unprofitable.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: MOC is unprofitable, and losses have increased over the past 5 years at a rate of 44.8% per year.

성장 가속화: Unable to compare MOC's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: MOC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.5%).


자기자본 수익률

높은 ROE: MOC has a negative Return on Equity (-38.4%), as it is currently unprofitable.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기